The influence of the calcium channel blocker verapamil on experimental glaucoma

International Ophthalmology

Volumn 25, Issue 2, 2004, Pages 75-79

  Mikheytseva, Irina N ^a,b   Kashintseva, Ludmila T ^a,b   Krizhanovsky, George N ^a,b   Kopp, Olga P ^a,b   Lipovetskaya, Elena M ^a,b  

^a FILATOV INSTITUTE OF EYE DISEASES AND TISSUE THERAPY   (Ukraine)

^b INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

Author keywords

Adrenalin; Ca2+ movement; Glaucoma; Pathogenesis; Rabbits; Verapamil

Indexed keywords

ADRENALIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR OUTFLOW; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG MECHANISM; GLAUCOMA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NONHUMAN; RABBIT; VASCULARIZATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; DISEASE MODELS, ANIMAL; EPINEPHRINE; GLAUCOMA; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS; RABBITS; VERAPAMIL;

EID: 3042542823     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:INTE.0000031737.08988.b0     Document Type: Article

References (16)

1. Krizhanovsky GN, Kashintseva LT, Lipovetskaya EM, Kopp OP. The role of adrenoreception in the development of primary glaucoma. Oftalmol Zh 1981; 9: 292-295 (Ukraine).
2. 2+ and cAMP messenger system in regulation of airway smooth muscle contraction. Amer J Physiol 1990; 258: 279-288.
3. Reuter H. Modulation of ion channels by phosphorylation and second messengers. News Physiol Sci 1987; 2: 167-171.
4. Krizhanovsky GN, Kashintseva LT, Mikheytseva IN, Lipovetskaya EM. Kopp OP. The cyclic nucleotides in experimental glaucoma. Byull Eksp Biol i Med 1988; 10: 419-421 (Russia).
5. Houslay M. "Crosstalk": a pivotal role for proteinkinase C in modulating relationships between signal transduction pathways. Europ J Biochem 1991; 19511: 2-27.
6. 2+ channels by β-adrenergic agonists. Proc Natl Acad Sci USA 1996; 93: 295-299.
7. Abelson M, Gilbert M, Smith L. Sustained reduction of intraocular pressure in humans with the calcium channel blocker Verapamil. Am J Ophthalmol 1988; 105: 155-159.
8. 2+ antagonist on visual field in low-tension glaucoma. Graefes Arch Clin Exp Ophthalmol 1989; 227: 408-412.
9. Serie JB, Schmidt KJ, Mittag TW, Schumer RA. Podos SM, Camras CB. Nifidipine and ocular blood flow. Invest Ophthalmol Vis Sci 1992; 33 (suppl.): 1279.
10. Hitchings RA. Therapeutic rational for normal tension glaucoma. Curr Opin Ophthalmol 1995; 2: 67-70.
11. Hitchings, RA, O'Brein, O'Sullivan. Intraocular pressure and circulation at the disc in glaucoma. Acta Ophthalmol Scand 1997; 75 (Suppl.): 15-22.
12. Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am J Ophthalmol 1993; 15: 608-613.
13. Pillunat LE, Lang GK. Calcium channel blockers and ocular carbodioxide reactivity in normal pressure glaucoma. X Congress Eur Soc of Ophthalmol 1995; 94.
14. Nethland P.A, Erickson K.A. Calcium channel blockers in glaucoma management. Ophthalmol Clin N Amer 1995; 2: 327-334.
15. Lin S, Araujo SV, Spaeth GL, Katz LJ, Smith M. Lack of effect of calcium channel blockers on open angle glaucoma. J Glaucoma 1996; 3: 187-190.
16. Santafe J, Martinez de Ibarreta MJ, Segarra J, Melena J. A long-lasting hypotensive effect of topical diltiazen on the intraocular pressure in conscious rabbits. Naunyn-Schmiedeberg's Arch of Pharmacol 1997; 355(5): 645-650.